PNT - POINT Biopharma Global GAAP EPS of -$0.23 beats by $0.07 revenue of $2.79M
2023-11-13 07:51:48 ET
More on POINT Biopharma Global
- Eli Lilly POINTs Toward Radiopharmaceutical Ambitions
- Eli Lilly extends expiration of tender offer to acquire Point Biopharma
- Point Biopharma quickly gains as big holder comes out against Eli Lilly deal
- Seeking Alpha’s Quant Rating on POINT Biopharma Global
- Historical earnings data for POINT Biopharma Global
For further details see:
POINT Biopharma Global GAAP EPS of -$0.23 beats by $0.07, revenue of $2.79M